Eddingpharm, a leading pharmaceuticals marketing company , signed a collaboration agreement with
GlaxoSmithKline China that gives Eddingpharm exclusive rights to market
and distribute Tykerb in China. Tykerb was recently approved by the SFDA
as a treatment for patients with HER2 positive breast cancer. The drug is indicated as a second-line treatment in patients with advanced or
metastatic cancer. Terms were not disclosed.
Eddingpharm focuses on in-licensing, marketing and distributing hospital pharmaceutical products. To date, Eddingpharm has been granted exclusive distribution rights of more than 10 products and achieved outstanding performance on marketed products.
Eddingpharm focuses on in-licensing, marketing and distributing hospital pharmaceutical products. To date, Eddingpharm has been granted exclusive distribution rights of more than 10 products and achieved outstanding performance on marketed products.
No comments:
Post a Comment
Please share your views to enrich the discussion